CNS Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note Payable

Note Payable	3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]
Note Payable	Note 3 – Note Payable On November 8, 2021, the Company entered into a short-term note payable for an aggregate of $425,990, bearing interest at 3.3% per year to finance certain insurance policies. Principal and interest payments related to the note will be repaid over a 11-month period with the final payment due on September 30, 2022. As of March 31, 2022 and December 31, 2021, the Company’s note payable balance was $272,572 and $387,794, respectively.

Note Payable

3 Months Ended

Mar. 31, 2022

Note 3 – Note Payable

On November 8, 2021, the Company entered into a short-term note payable for an aggregate of $425,990, bearing interest at 3.3% per year to finance certain insurance policies. Principal and interest payments related to the note will be repaid over a 11-month period with the final payment due on September 30, 2022. As of March 31, 2022 and December 31, 2021, the Company’s note payable balance was $272,572 and $387,794, respectively.